Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreClinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial
Type de publicationJournal Article
Year of Publication2019
AuteursBidard F-C, Jacot W., Dureau S., Brain E., Bachelot T., Bourgeois H., Goncalves A., Ladoire S., Naman H., Dalenc F., Gligorov J., Espie M., Levy C., Ferrero J-M, Loirat D., Cottu P., Dieras V., Simondi C., Berger F., Alix-Panabieres C., Pierga J-Y
JournalCANCER RESEARCH
Volume79
Date PublishedFEB
Type of ArticleMeeting Abstract
ISSN0008-5472
DOI10.1158/1538-7445.SABCS18-GS3-07